Amgen and Allergan's Phase III trial of ABP 215 meets primary and secondary endpoints

Amgen and Allergan have reported positive results from a Phase III trial that evaluated the efficacy and safety of ABP 215 compared with Avastin (bevacizumab) in adults with advanced non-squamous, non-small cell lung cancer (NSCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

CONCLUSION: Overall, results showed that Fvax is a potential vaccine against NSCLC. The approach of this study efficiently minimized the number of tests, cost and time required to select the best epitopes and to design a vaccine for the treatment of NSCLC.. PMID: 32856858 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Tests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the latest with diagnostic contributions. Waltham, MA-based Thermo Fisher is the second company to be granted an Emergency Use Authorization for a commercially developed COVID-19 test. MD+DI reported Roche received this designation late last week too for the cobas SARA-COV-2 test. In a press release, Thermo Fisher said the authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Regulatory and Compliance Source Type: news
AbstractBackgroundImmunotherapy with checkpoint inhibition has gained high importance for oncological treatments with benefits in overall survival (OS). However these drugs are not harmless, and immune related adverse events (irAE) have been reported. We pretend to evaluate which patients (pts) are in risk for developing these.MethodsRetrospective evaluation of all pts treated with PD-1 and PD-L1 inhibitors for solid tumors in our center, during January 2015 and October 2018. A multivariate regression was made to determine potential risk factors for irAE. Significance was stablished at p  
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Immunotherapy appears to be safe and effective for treating non-small-cell lung cancer (NSCLC) in older people, researchers from Italy report.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
In patients with non-small-cell lung cancer (NSCLC), the presence of tumor protein p53 (TP53) and ataxia-telangiectasia mutated (ATM) comutation might indicate better response to immune-checkpoint inhibitors (ICIs), according to Chinese researchers.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
The expression of programmed death ligand 1 (PD-L1) is common in locally advanced or metastatic non-small-cell lung cancer (NSCLC), according to a retrospective study across 18 countries.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Adopting expanded inclusion criteria for clinical trials would nearly double the percentage of patients with advanced non-small-cell lung cancer (NSCLC) who are eligible to enroll, according to new research.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
As first-line treatment for metastatic non-squamous non-small-cell lung cancer (NSCLC), the anti-PD-L1 agent atezolizumab (Tecentriq, Genentech) in combination with chemotherapy boosts survival compared with chemotherapy alone, according to a company-funded study.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy | Avastin | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals